Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the transaction, the chief executive officer now owns 143,603 shares of the company’s stock, valued at $5,993,989.22. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 18th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $43.07, for a total value of $753,725.00.
• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.94, for a total value of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.39, for a total value of $782,556.25.

Vera Therapeutics Price Performance

NASDAQ:VERA traded down $5.17 during trading hours on Friday, hitting $37.02. 940,406 shares of the stock were exchanged, compared to its average volume of 513,118. The firm’s fifty day moving average price is $45.55 and its 200 day moving average price is $40.95. Vera Therapeutics, Inc. has a 52-week low of $14.20 and a 52-week high of $51.61. The company has a market cap of $2.34 billion, a P/E ratio of -14.18 and a beta of 1.15. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Vera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of VERA. Samlyn Capital LLC raised its holdings in Vera Therapeutics by 90.8% in the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after acquiring an additional 586,410 shares during the last quarter. First Light Asset Management LLC increased its holdings in shares of Vera Therapeutics by 130.6% in the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after purchasing an additional 569,590 shares during the last quarter. American Century Companies Inc. purchased a new position in Vera Therapeutics during the second quarter worth approximately $14,015,000. Logos Global Management LP lifted its position in Vera Therapeutics by 65.2% during the second quarter. Logos Global Management LP now owns 950,000 shares of the company’s stock worth $34,371,000 after buying an additional 375,000 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new stake in Vera Therapeutics in the 2nd quarter valued at $10,492,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a report on Tuesday, October 1st. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They set an “overweight” rating and a $70.00 target price on the stock. Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Wedbush upped their price target on Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $63.50.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.